The State Street SPDR S&P Biotech ETF, which trades under the ticker XBI, was down 2.1% on Monday morning, a sign of a shift ...

Both biotechs are a bit risky, but could benefit from clinical progress this year -- and the upside would be huge. CRISPR has ...

Welcome to Fierce Biotech's fifth annual layoff tracker, a resource designed to keep pace with the sector's steady stream of ...

Several Bay Area biotech companies announced big funding rounds totaling hundreds of millions of dollars just before the ...

With partner Eli Lilly’s help, the radiopharmaceutical drugmaker priced one of the sector’s largest new stock offerings in ...

Medpace HoldingsMEDP is Tuesday's IBD Stock Of The Day. Shares are testing an early entry as the biotech funding environment ...

Travere Therapeutics Stock (TVTX) is plummeting on news of a potential FDA delay for its kidney disease treatment ...

The companies Kymera Therapeutics, Immunovant, and Dyne Therapeutics bagged the biggest biotech funding rounds overall in ...

It sounds like Lilly did just that. The U.S. pharma announced Wednesday that it was paying $14 per share of Ventyx—more than ...

XBI biotech ETF surged 65% as M&A heats up, but 2026 brings headwinds and tougher gains. Click here for a detailed analysis.

Biotech investors spent years waiting for the sector to recover from its brutal 2021 peak. That patience is finally paying ...

A bevy of other companies also brought in money on Thursday, including Alveus Therapeutics, Diagonal Therapeutics, ...